首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1410101

全球細胞分離市場：預測（2023-2028）

Cell Separation Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021年全球細胞分離市場規模達72.94億美元。

預計細胞分離市場將在整個預測期內穩定成長。細胞分離是指從混合物或細胞群中分離特定類型細胞的過程。癌症等慢性病盛行率的增加和生物製藥行業的擴張是細胞分離市場的主要成長動力。此外，對細胞分離市場的投資增加、意識的提高和幹細胞研究計劃正在進一步推動細胞分離市場的發展。

慢性疾病和感染疾病的負擔增加

癌症、心臟病和自體免疫疾病等慢性疾病持續對全球健康產生嚴重影響。分離細胞的技術對於了解疾病原因、尋找疾病生物標記和製定專門的治療方法至關重要。透過分離和分析循環性腫瘤細胞(CTC)，醫生可以微創監測癌症患者對各種治療的反應。因此，癌症等慢性疾病病例的增加預計將加強細胞分離市場。例如，根據世界衛生組織的數據，2020 年約有 1,000 萬人（約六分之一的死亡人數）死於癌症，使其成為全球主要死亡原因。

不斷發展的生物製藥產業

隨著新療法和生技藥品研發投資的增加，生物製藥產業正在不斷擴張。細胞分離技術對於單株抗體、重組蛋白和細胞療法的生產至關重要。根據國家投資促進和便利化局的數據，生物製藥產業是世界第三大產業。生物製藥產業投資的增加直接推動了細胞分離市場的發展。例如，美國研究與製藥工業協會 (PhRMA) 報告稱，2019 年僅美國生物製藥研究機構的研發支出就超過 1,000 億美元。此外，Sun Pharma 董事總經理於 2022 年 2 月宣布投資 600-650 美元用於研究。

人們對幹細胞研究的認知不斷增強

幹細胞研究在再生醫學、疾病建模和藥物開發方面具有巨大潛力。幹細胞的分離和表徵需要有效的細胞分離技術。人們對幹細胞研究和各種調查的認知不斷提高，正在推動細胞分離市場的發展。再生醫學創新計劃是根據2021年《21世紀治療方法》設立的。該舉措由 NIH 和 FDA 採取，旨在加速幹細胞領域的進展。此外，加州再生醫學研究所將十月的第二個星期三慶祝為“幹細胞意識日”，以共用有關幹細胞和再生醫學的想法、想法和進展。

加大投資力道和政府支持

參與細胞分離解決方案的公司獲得的投資和資金的增加預計將在未來幾年推動細胞分離市場的發展。例如，Nodexus Inc.籌集了 3000 萬美元資金，以推進和擴大其 NX One 平台的商業化。 NX One 平台是世界上第一個用於從生物樣本中分選和分離單細胞的自適應系統。此外，政府對推廣細胞分離解決方案的支持和津貼進一步推動了細胞分離市場的發展。例如，Proteios Technology Inc. 於 2022 年 9 月獲得 NIH 的 160 萬美元津貼，用於將其多元細胞分離技術商業化。

市場抑制因素

儘管細胞分離市場正在經歷成長和開拓，但一些抑制因素和挑戰可能會影響其擴張。細胞分離的專一性可能受到所採用的分離方法的限制。例如，使用磁珠的分離技術可以因為特異性結合而共分離非目標細胞。一些細胞分離技術，例如螢光激活細胞分選 (FACS) 和微流體技術，需要專門的技術知識才能使用和理解結果。貧窮國家缺乏專家可能會阻礙細胞分離市場的擴張。一些細胞分離方法具有通量和可擴展性限制。當處理大量樣品時，這可能是一個限制。

預計北美地區將出現顯著成長

預計在預測期內，北美將佔據細胞分離市場的主要佔有率。造成這一佔有率的因素包括成熟的製藥和生物技術領域以及美國最尖端科技的廣泛使用。例如，2022 年 9 月，美國總統推出了生物技術和生物製造舉措，以充分發揮生物技術的潛力。此外，該地區慢性病的高盛行率增加了對細胞分離產品的需求，從而推動了細胞分離市場的發展。例如，根據 CDC 的數據，癌症是美國第二大死因，2021 年約有 190 萬例癌症。

主要市場參與者

Terumo Corporation 是一家日本跨國公司，致力於開發各種醫療設備，包括細胞分離相關產品。透過 Terumo BCT（血液成分技術）分店，我們提供各種細胞分離和處理技術。默克公司是一家總部位於德國的全球科技公司。我們提供與細胞分離及鄰近產業相關的各種產品和服務。 Estapor (R) 順磁性微球是可以使用簡單的磁性方法分離目標細胞和微生物的試劑。 STEMCELL Technologies Inc.是一家加拿大生物技術公司，專注於幹細胞研究、細胞治療和再生醫學領域的研究、開發、工具、試劑和服務。 Robosep(TM)-C 人類 T 細胞分離試劑盒、Robosep(TM)-C 管道套件是該公司作為細胞分離解決方案提供的部分產品。

新興市場的主要發展

2023年5月，Akadeum推出了用於T細胞分離和擴增的GMP級產品線。本產品能夠直接分離白斑人體免疫細胞，並透過微氣泡活化T細胞來活化T細胞。 2022 年 2 月，GPB Scientific 宣布推出 Curate® Cell 平台，以簡化細胞治療和分離流程。 2020年6月，LevitasBio推出了其旗艦產品LeviCeIITM，作為細胞分離和分選的新方法。它提供了一種快速可靠的方法來分選完全存活的細胞群，同時提供無標定細胞分離。

The cell separation market is anticipated to grow at a steady pace throughout the forecast period. Cell separation refers to the process of separating specific types of cells from a mixture or population of cells. The growing prevalence of chronic diseases such as cancer and the expanding biopharmaceutical industry is a major growth driver of the cell separation market. Moreover, the increasing awareness and stem research projects along with the increasing investments in the cell separation market further propelling the cell separation market.

Growing Burden of Chronic and Infectious Diseases

Chronic conditions including cancer, heart disease, and autoimmune illnesses continue to have a serious impact on world health. Techniques for separating cells are essential for understanding disease causes, finding illness biomarkers, and creating specialized treatments. Physicians can monitor how cancer patients respond to various therapies with a minimum of invasiveness by isolating and analyzing circulating tumor cells (CTCs). Therefore, the rising cases of chronic conditions such as cancer are contemplated to bolster the cell separation market. For instance, roughly 10 million deaths, or roughly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally according to the WHO.

Growing Biopharmaceutical Industry

The biopharmaceutical industry is expanding, with increasing investments in research and development of novel therapies and biologics. Cell separation techniques are critical in the production of monoclonal antibodies, recombinant proteins, and cell-based therapies. The biopharmaceutical industry is 3rd largest sector in the world as per the National Investment Promotion & Facilitation Agency (India). The rising investment in the biopharmaceutical industry is directly boosting the cell separation market. For instance, Pharmaceutical Research and Manufacturers of America (PhRMA) reports that over $100 billion was spent on R&D by biopharmaceutical research businesses in the US alone in 2019. Moreover, the managing director of Sun Pharma announced an investment of $600 - $650 in research in February 2022.

Rising Awareness about Stem Cell Research

The study of stem cells has enormous potential for regenerative medicine, disease modeling, and medication development. Effective cell separation techniques are needed for the isolation and characterization of stem cells. The rising awareness about stem cell research and various studies are boosting the cell separation market. The Regenerative Medicine Innovation project was established by the 21st Century Cures Act which was concluded in 2021. The initiative was taken by NIH and FDA to accelerate progress in the field of stem cells. Moreover, the second Wednesday of October is celebrated as Stem Cell Awareness Day by the California Institute for Regenerative Medicine to share the thoughts, ideas, and progress they have made in stem cells and regenerative medicine.

Increasing Investment Initiatives and Government Support

The increasing investments and funding received by the companies involved in cell separation solutions are expected to propel the cell separation market in the coming years. For example, Nodexus Inc. raised $30 million in funding to advance and expand the commercialization of the NX One platform. The NX One platform is the world's first adaptable system to sort and isolate single cells from biological samples. Moreover, government support and grants to advance cell separation solutions are further boosting the cell separation market. For example, Proteios Technology Inc. was awarded a $1.6 million grant from NIH to commercialize its multivariate cell isolation technology in September 2022.

Restraints in the Market

The cell separation market has experienced growth and development, however, some restraints or challenges can impact its expansion. The specificity of cell separation may be constrained by the separation method employed. For example, non-target cells may be co-isolated using magnetic bead-based separation techniques as a result of non-specific binding. To use and comprehend the results of some cell separation techniques, such as fluorescence-activated cell sorting (FACS) or microfluidics, specialized technical knowledge is needed. The lack of experts in poor countries may hinder the cell separation market expansion in the regions. Some cell separation approaches could have throughput and scalability restrictions. This might be a limitation when processing big sample quantities.

North America is anticipated to grow considerably.

North America is expected to hold a significant share of the cell separation market during the forecast period. The factors attributed to such a share are the well-established pharmaceutical and biotech sectors as well as the widespread use of cutting-edge technologies in the US. For instance, the US president launched a biotechnology and biomanufacturing initiative in September 2022 to harness the full potential of biotechnology in the country. Moreover, the higher prevalence of chronic diseases in the region further indicates the need for cell separation products thereby boosting the cell separation market. For instance, cancer is the second-most leading cause of death in the US as per the CDC with around 1.9 million cases in 2021.

Major Market Players

Terumo Corporation is a Japanese multinational company that is involved in the development of a wide range of medical devices including products related to cell separation. Through its Terumo BCT (Blood Component Technologies) branch, Terumo provides a range of cell separation and processing technologies.
Merck KGaA is a global science and technology company headquartered in Germany. It provides a range of products and services linked to cell separation and adjacent industries. Estapor® Paramagnetic Microspheres are reagents that enable the isolation of desired cells or microorganisms using a straightforward magnet-based approach.
STEMCELL Technologies Inc. is a Canadian biotechnology company that focuses on the research, development, and provision of tools, reagents, and services for the fields of stem cell research, cell therapy, and regenerative medicine. Robosep™ - C Human T Cell Isolation Kit, and RoboSep™ -C Tubing Set are some of the products offered by the company as cell separation solutions.

Key Market Developments

In May 2023, Akadeum launched a GMP-grade product line for T-cell isolation and expansion. The product uses microbubbles to activate T cells which enable direct leukoplakia human immune cell isolation and T cell activation.
In February 2022, GPB Scientific launched its go-to-market Curate® Cell platform to streamline the process of cell therapies and separation.
In June 2020, LevitasBio introduced LeviCeIITM, its main product, as a novel approach for cell separation and sorting. It offers a quick, dependable way to sort completely viable cell populations while providing label-free cell separation.

Segmentation:

By Product

Consumables
Instruments

By Technique

Centrifugation
Surface Marker
Filtration

By Application

Biomolecule Isolation
Cancer Research
Stem Cell Research
Tissue Regeneration
In Vitro Diagnostics
Therapeutics

By End-Use

Research Laboratories and Institutes
Hospitals and Diagnostic Laboratories
Cell Banks
Biotechnology and Biopharmaceutical Companies

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CELL SEPARATION MARKET, BY PRODUCT

5.1. Introduction
5.2. Consumables
5.3. Instruments

6. CELL SEPARATION MARKET, BY TECHNIQUE

6.1. Introduction
6.2. Centrifugation
6.3. Surface Marker
6.4. Filtration

7. CELL SEPARATION MARKET, BY APPLICATION

7.1. Introduction
7.2. Biomolecule Isolation
7.3. Cancer Research
7.4. Stem Cell Research
7.5. Tissue Regeneration
7.6. In Vitro Diagnostics
7.7. Therapeutics

8. CELL SEPARATION MARKET, BY END-USE

8.1. Introduction
8.2. Research Laboratories and Institutes
8.3. Hospitals and Diagnostic Laboratories
8.4. Cell Banks
8.5. Biotechnology and Biopharmaceutical Companies

9. CELL SEPARATION MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. The Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others